Five-year outcomes of the randomized REDUCE study showed a continuous benefit from patent foramen ovale (PFO) closure compared with antiplatelet agents to prevent cryptogenic strokes. The most important aspect of this result seems to be the idea that PFO closure in selected patients offers durable benefit with guaranteed long-term safety. The original results from REDUCE...
We thank all the presenters of the Peru Sessions2018 who shared their presentations to contribute to our mission of promoting scientific dissemination in the field of Interventional Cardiology in Latin American level. See them below. Dr. Marcelo Halac: “Enfermedad Cardiovascular en la Mujer: Características que la hacen diferente”. (Spanish version) ...
Patent foramen ovale closure is the standard treatment for cryptogenic stroke patients. However, there are is little information on its long-term evolution. The aim of this study was to determine clinical outcomes (death, ischemic or bleeding events) after foramen ovale closure over a 10-year evolution. The study included 201 consecutive patients (mean age 47...
High risk patent foramen ovale closure PFO resulted in reduced stroke, vascular death and bleeding risk. Recent reports have shown a favorable role of PFO in patients with cryptogenic stroke, though with some unclear results, which immediately raised the questions: Who are the optimal candidates for this procedure, and who will see no benefit? ...
Courtesy of Dr. José Álvarez. This is a multicenter randomized study on patients with patent foramen ovale (PFO) and a first episode of cryptogenic stroke. It only included patients with moderate to large shunt based on the number of bubbles observed in the left atrium within the first three beats after being noticed in the...